Geron (GERN) Competitors

Geron logo
$2.56 -0.23 (-8.24%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$2.58 +0.02 (+0.98%)
As of 02/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GERN vs. ALKS, IONS, FOLD, LGND, BCRX, DVAX, MNKD, CLDX, NVAX, and INVA

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.

Geron vs.

Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.

Alkermes presently has a consensus target price of $37.25, indicating a potential upside of 3.79%. Geron has a consensus target price of $7.25, indicating a potential upside of 183.20%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Geron
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.09

Alkermes has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 3.1% of Geron shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.66B3.49$355.76M$1.9518.41
Geron$240K6,448.00-$184.13M-$0.32-8.00

Alkermes received 207 more outperform votes than Geron when rated by MarketBeat users. Likewise, 70.52% of users gave Alkermes an outperform vote while only 70.07% of users gave Geron an outperform vote.

CompanyUnderperformOutperform
AlkermesOutperform Votes
701
70.52%
Underperform Votes
293
29.48%
GeronOutperform Votes
494
70.07%
Underperform Votes
211
29.93%

Alkermes has a net margin of 22.15% compared to Geron's net margin of -682.48%. Alkermes' return on equity of 24.92% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes22.15% 24.92% 14.55%
Geron -682.48%-67.53%-45.46%

In the previous week, Alkermes had 38 more articles in the media than Geron. MarketBeat recorded 41 mentions for Alkermes and 3 mentions for Geron. Geron's average media sentiment score of 0.92 beat Alkermes' score of 0.48 indicating that Geron is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
7 Very Positive mention(s)
7 Positive mention(s)
20 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Geron
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alkermes beats Geron on 13 of the 19 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.55B$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio-8.009.7126.2219.45
Price / Sales6,448.00290.45456.5777.34
Price / CashN/A75.4646.0638.90
Price / Book5.575.537.355.05
Net Income-$184.13M$123.46M$3.19B$222.81M
7 Day Performance-9.22%1.37%1.69%1.29%
1 Month Performance-11.42%2.09%4.13%1.52%
1 Year Performance27.36%1.28%22.24%16.53%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
3.3966 of 5 stars
$2.56
-8.2%
$7.25
+183.2%
+27.4%$1.55B$240,000.00-8.0070High Trading Volume
ALKS
Alkermes
3.4463 of 5 stars
$31.33
-0.8%
$36.00
+14.9%
+11.5%$5.08B$1.66B16.092,100Earnings Report
Analyst Forecast
Insider Trade
Analyst Revision
IONS
Ionis Pharmaceuticals
4.0017 of 5 stars
$31.21
-0.6%
$60.65
+94.3%
-30.1%$4.93B$788M-12.81800Short Interest ↑
FOLD
Amicus Therapeutics
4.0052 of 5 stars
$9.61
-0.5%
$16.88
+75.7%
-29.0%$2.88B$399.36M-28.35480News Coverage
LGND
Ligand Pharmaceuticals
4.1543 of 5 stars
$115.46
+0.2%
$147.00
+27.3%
+62.9%$2.18B$131.31M45.9880News Coverage
Positive News
BCRX
BioCryst Pharmaceuticals
4.0491 of 5 stars
$8.54
-2.1%
$15.50
+81.6%
+52.9%$1.78B$331.41M-14.11530
DVAX
Dynavax Technologies
4.2493 of 5 stars
$13.26
+0.8%
$23.00
+73.5%
+3.3%$1.75B$232.28M102.12350
MNKD
MannKind
2.898 of 5 stars
$5.61
-0.4%
$9.21
+64.4%
+48.5%$1.55B$267.20M80.50400Gap Up
CLDX
Celldex Therapeutics
1.5509 of 5 stars
$21.58
-4.0%
$62.25
+188.5%
-40.7%$1.43B$6.88M-8.37150Upcoming Earnings
Analyst Revision
News Coverage
NVAX
Novavax
4.1622 of 5 stars
$8.19
+0.7%
$17.83
+117.9%
+96.9%$1.31B$983.71M-3.631,543
INVA
Innoviva
2.9541 of 5 stars
$18.21
-1.1%
N/A+14.0%$1.14B$310.46M26.41100Short Interest ↓
News Coverage

Related Companies and Tools


This page (NASDAQ:GERN) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners